shutterstock_104834144.jpg

Client News

From the CEO

2014

 

September 04, 2014  MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global
Investment Conference on September 10, 2014

September 04, 2014  Matinas BioPharma to Present at Three Investor Conferences in September

August 14, 2014   MYOS Corporation Reports 2014 second Quarter Results

August 7, 2014   MYOS Corporation to Announce Second Quarter 2014 Financial Results on August 14

July 31, 2014   Matinas BioPharma Launches Digital Corporate Communication Channels

July 30, 2014   MYOS Corporation Announces Appointment of Douglas Weekes as Chief Commercial Officer

July 25, 2014   MYOS Corporation Extends Manufacturing and Supply Agreement for Fortetropin

July 23, 2014  AntriaBio Appoints Barry Sherman, M.D.to Its Board of Directors

July 22, 2014  Matinas BioPharma Holdings, Inc. Common Stock Commences Trading on OTCBB 
Under Ticker Symbol MTNB

July 17, 2014  MYOS Corporation Announces Agreement With Cloud Pharmaceuticals, Inc. to Develop Small Molecules Targeting Sarcopenia and Cachexia

July 14, 2014  MYOS Corporation Appoints World Renowned Scientific Visionary and Entrepreneur,
J. Craig Venter, Ph.D., to Board of Directors

July 09, 2014  MYOS Corporation Announces Approval for Listing on the NASDAQ Capital Market

June 26, 2014  MYOS Corporation Sponsors SixthAnnual Edition of Scientific American Worldview

June 23, 2014  AntriaBio Appoints C. Ronald Kahn, M.D. to Its Scientific Advisory Board

May 22, 2014  AntriaBio, Inc. to Present at the Third Annual Marcum MicroCap Conference
on Thursday, May 29, 2014

May 12, 2014  AntriaBio, Inc. Establishes Manufacturing and Laboratory Facility in Colorado